Breast cancer: METTL16 promotes the progression of breast cancer by inhibiting ferroptosis by epigenetically increasing GPX4 expression via m6A modification.225 The m6A modification level is reduced due to downregulation of METTL14 in anti-HER2 therapy-resistant breast cancer. Here, ERBB2 is linked to breast carcinoma.